about
Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer.A pilot study combining a GC-sensor device with a statistical model for the identification of bladder cancer from urine headspace.A non-invasive miRNA based assay to detect bladder cancer in cell-free urine.Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms?Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells.Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer.Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records.Is photodynamic diagnosis ready for introduction in urological clinical practice?Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?Tackling non-muscle invasive bladder cancer in the clinic.Predictors of costs associated with radical cystectomy for bladder cancer: A population-based retrospective cohort study in the province of Quebec, Canada.Stage, grade and pathological characteristics of bladder cancer in the UK: British Association of Urological Surgeons (BAUS) urological tumour registry.[Quality of care in patients with newly diagnosed bladder cancer: a prospective assessment in northern Germany].The value of the UroVysion® FISH assay in the risk-stratification of patients with "atypical urothelial cells" in urinary cytology specimens.Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization.
P2860
Q33976936-095AAE7C-3EC8-45FC-83F1-DA1798016873Q34828645-F0B1CCB9-9389-4B88-98EF-9F89268A6A90Q36420310-CCE66C27-3456-4806-B96E-ADE1849723C3Q37007328-2334390A-C047-44BD-B32B-E67A50E3EE79Q37182161-24BBFD63-CE18-48C6-A90D-BAAD8401BD76Q37376339-07B513E5-685D-4667-BD04-AA9DD80D1E51Q37672870-12A184E7-BA33-4580-867D-A9F30FD2D99DQ37911769-09F71408-6DDC-4DB9-BEBC-5CCB2D33F910Q38114946-D59AC0D6-7724-4375-9E80-454625036D28Q38542639-F89F4AD7-16A2-44F9-81C4-0E49368A341FQ39209020-2F9FF53F-749F-4C14-928A-3446954F61ABQ41027602-DFF83A1C-ED83-42BB-8A4D-93DDDA6D762FQ43862733-BFA52786-B554-46A2-84C6-53FBAD5D7C24Q44701036-09B276A0-9165-4326-B9DA-E0EB85C3E2CBQ48292323-7F5924E9-167C-4558-90F1-575E5D5E2D24Q48914536-E148C9FA-AF2C-478F-BBB5-0520CAB0A506
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Can we still afford bladder cancer?
@en
Can we still afford bladder cancer?
@nl
type
label
Can we still afford bladder cancer?
@en
Can we still afford bladder cancer?
@nl
prefLabel
Can we still afford bladder cancer?
@en
Can we still afford bladder cancer?
@nl
P2093
P1476
Can we still afford bladder cancer?
@en
P2093
Arnulf Stenzl
David Schilling
Joerg Hennenlotter
P304
P356
10.1097/MOU.0B013E32830B8925
P577
2008-09-01T00:00:00Z